Endometrial Cancer

Opening her discussion on a patient case of recurrent endometrial cancer, Ritu Salani, MD, MBA, highlights the evolving role of molecular testing in this setting.

Robert L. Coleman, MD, opens discussion on a second patient case and highlights critical aspects of mismatch repair deficient (dMMR) recurrent endometrial carcinoma.

Before closing out their discussion on the first patient case, key opinion leaders on endometrial carcinoma reflect on the optimal selection and sequencing of therapy in pMMR recurrent disease.

A trial of TOS-358, a first-in-class covalent PI3Kα inhibitor, for various solid tumors dosed its first patient.

An artificial intelligence model has been shown to predict the risk of low and high distant recurrence in patients with endometrial cancer.

Wesley Burkett, MD, discusses some novel targets that are available and being evaluated in the endometrial cancer space.

Expert panelists provide their perspective on the real-world use of combination lenvatinib + pembrolizumab in patients with MMRp recurrent endometrial carcinoma.

Moderator Robert L. Coleman, MD, spearheads a review of clinical data from KEYNOTE 775, which combined lenvatinib with pembrolizumab in patients with endometrial carcinoma.

The addition of dostarlimab to standard combination chemotherapy in the phase 3 RUBY study showed a significant survival improvement in patients with primary advanced or recurrent endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™, Robert W. Holloway, MD, discussed with participants later-line systemic therapy options for patients with recurrent/metastatic endometrial cancer.

Key opinion leaders in the field of endometrial carcinoma management share advice on optimal patient monitoring and the identification of recurrent disease.

Shared insight on the advent of molecular testing in patients with endometrial carcinoma and how it helps inform the treatment pathway.

Experts Michael J. Birrer, MD, PhD, and Kimberly Halla, MSN, FNP-C, share insight to a typical patient presentation of MMRp recurrent endometrial carcinoma.

Opening its discussion on endometrial carcinoma, a panel of experts led by Robert L. Coleman, MD, reflects on a patient with mismatch repair proficient (MMRp) recurrent disease.

New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.

In the NRG GY018 trial, the addition of pembrolizumab to standard-of-care chemotherapy followed by maintenance pembrolizumab demonstrated a reduction in risk of disease progression or death in patients with advanced or recurrent endometrial cancer.

Early responses were shown with to lenvatinib plus pembrolizumab in the mismatch repair proficient and all-comer populations of patients with advanced endometrial cancer.

The phase 1b SOLAR trial which evaluated olaparib plus selumetinib in patients with RAS-mutated ovarian or endometrial cancer showed there to be a clinical benefit with the combination.

A correlation in total scores were seen between the gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire, according to findings presented at the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Thomas J. Herzog, MD, discussed the results of the KEYNOTE-775 trial of lenvatinib plus pembrolizumab versus chemotherapy in patients with advanced endometrial cancer.

Casey M. Cosgrove, MD, discusses biomarker-guided treatment for endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bhavana Pothuri, MD, MS, discussed with participants their experiences managing adverse events of immunotherapy for advanced endometrial cancer.

David O’Malley, MD, discusses the background and updated results of the KEYNOTE-158 trial looking at pembrolizumab monotherapy in patients with advanced endometrial cancer.

A regular approval has been granted to dostarlimab for the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.

Early findings from the phase 2 OATH trial show treatment with ONA-XR plus anastrozole elicits a 4-month progression- free survival rate of 77% and overall response rate of 22% in patients with HR-positive metastatic endometrial cancer.

During a Targeted Oncology case-based roundtable event, Robert Coleman, MD, discussed dosing of lenvatinib plus pembrolizumab in patients with endometrial carcinoma.

The phase 3 NRG-GY018 trial of pembrolizumab and standard of care chemotherapy led to a clinically meaningful improvement in progression-free survival vs standard of care alone in endometrial carcinoma regardless of mismatch repair status.

According to a follow-up analysis of the phase 1b/2 study 111/KEYNOTE-146, lenvatinib/pembrolizumab continued to show tumor responses, overall survival, and progression-free survival benefits in endometrial cancer.

Due to its potential to fill a treatment gap in the HER-low and HER-positive endometrial cancer space, DB-1303 now has an FDA fast track designation.

Robert Holloway, MD, highlights the issue of racial disparity in endometrial cancer, and the critical unmet needs for patients.